After being voted down by an FDA panel last month, Sarepta Therapeutics Inc.’s (SRPT) Duchenne Muscular Dystrophy drug candidate Eteplirsen awaits the regulatory agency’s final decision, which is set for May 26, 2016.
Forex – financial instrument.Forex news
After being voted down by an FDA panel last month, Sarepta Therapeutics Inc.’s (SRPT) Duchenne Muscular Dystrophy drug candidate Eteplirsen awaits the regulatory agency’s final decision, which is set for May 26, 2016.